Acute hepatitis C: Current status and remaining challenges
| Autor: | Teresa Santantonio, J. Tilman Gerlach, Johannes Wiegand |
|---|---|
| Rok vydání: | 2008 |
| Předmět: |
medicine.medical_specialty
Hepatitis C virus Hepacivirus Acute hepatitis C Alpha interferon Antiviral therapy medicine.disease_cause Antiviral Agents Pegylated interferon alfa chemistry.chemical_compound Risk Factors Epidemiology medicine Humans Intensive care medicine Hepatitis Hepatology biology Transmission (medicine) business.industry Ribavirin Hepatitis C virus (HCV) biology.organism_classification medicine.disease Hepatitis C Regimen chemistry Acute Disease Practice Guidelines as Topic Immunology Interferon alfa business |
| Zdroj: | Journal of Hepatology. 49:625-633 |
| ISSN: | 0168-8278 |
| Popis: | The acute phase of hepatitis C virus (HCV) infection represents a key point in the evolution of hepatitis C. In some patients, the infection resolves spontaneously, whereas in others it develops into chronic disease. However, because acute hepatitis C is often asymptomatic, detection and diagnosis are usually difficult. What is more, there are no established treatment guidelines, leaving physicians to make several challenging decisions, such as whether to treat, when to treat and what treatment regimen to use. Pegylated interferon alfa monotherapy is most commonly used to treat patients with acute hepatitis C; the role of ribavirin has yet to be established. In this review, we discuss the epidemiology of acute hepatitis C, its risk factors and routes of transmission and current treatment practices. We also discuss data from published clinical studies and focus on unresolved issues for which additional studies are needed in order to establish standardized treatment guidelines for the management of acute hepatitis C. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect